Pharmacy Technician

PTCB Recertification and State Required CE

START NOW

Pharmacist

Pharmacists Library

All the CE you need for 1 year to meet state requirements just $97.00.

START NOW
oatph
Expired activity
Please go to the POWER-PAK C.E.® homepage and select a course.

Novel Treatments to Overcome Clinical Challenges in Treating Major Depressive Disorder

Provided by The College of Psychiatric and Neurologic Pharmacists (CPNP), in cooperation with ASiM.
Supported by educational grants from Alkermes, Takeda Pharmaceuticals U.S.A., Inc, and Lundbeck.

OVERVIEW

Despite a number of distinct medication classes, only one-third of patients with major depressive disorder (MDD) achieve remission with initial antidepressant therapy, and a substantial number of patients fail to achieve remission after as many as 4 acute treatment trials. Furthermore, many patients who respond to antidepressant therapy may experience residual symptoms that negatively affect their quality of life and increase the likelihood of relapse. There are a number of treatment strategies for managing patients with difficult-to-treat depression, treatment-resistant depression, and residual symptoms of depression; a number of these strategies include agents of novel, unconventional mechanisms of action. This archived live symposium will highlight recently approved and investigational agents for treating patients with MDD along with novel approaches to individualized therapy. Pharmacist-driven strategies to maintain MDD treatment goals and optimize patient outcomes will also be discussed.

GOAL

The goal of this activity is to provide up-to-date comprehensive information for psychiatric pharmacist specialists on the treatment and management of patients with MDD.

TARGET AUDIENCE

This initiative has been designed to meet the educational needs of psychiatric pharmacists. There are no prerequisites.

LEARNING OBJECTIVES

Upon the conclusion of this activity, the participant should be able to:

  • DESCRIBE recently approved antidepressants and other novel treatments and their implications in treating MDD.
  • DISCUSS practical strategies that incorporate novel approaches to individualized MDD therapy.
  • IMPLEMENT pharmacist-driven or nursing-driven approaches to work with patients and one another to attain and maintain MDD treatment goals.

CONTINUING EDUCATION CREDIT AND DISCLOSURES

Accreditation Statements
The College of Psychiatric and Neurologic Pharmacists (CPNP) is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

CONTINUING EDUCATION INFORMATION

Pharmacist Credit:
acpeThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This enduring material provides 1.5 contact hours of knowledge-based credit (0.15 CEUs) from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-9999-17-060-H01-P.

NABP e-PROFILE ID NUMBER: Your CE credits will be submitted electronically to the NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

Type of Activity: Knowledge

Published: December 11, 2017
Expires: December 11, 2018

Media:  Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes

STEERING COMMITTEE

Patricia Cunningham, DNSc, APRN-BC
Associate Professor
Arkansas State University
Jonesboro, Arkansas
Dr Cunningham reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Patrick R. Finley, PharmD, BCPP
Professor of Clinical Pharmacy
School of Pharmacy
University of California at San Francisco
San Francisco, California
Dr Finely reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

The planners and managers have nothing to disclose related to the content of this CE activity. CPNP Executive Director, Brenda Schimenti, Medical Director, Ankita Patel, PharmD, and Senior Medical Editor, Lisa Mangione, all have nothing to disclose related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE AND DISCLAIMER

Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). Dr Finley's presentation may include discussion of off-label, experimental, and/or investigational use of drugs or devices of ketamine. The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

FAIR BALANCE AND INTEGRITY STATEMENT

It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (eg, their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.

ACTIVITY INSTRUCTIONS AND HOW TO EARN CREDIT

The following is an archived symposium activity, comprised of synced slides with audio, designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, the symposium archive activity, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.

Participants must complete the activity as described above. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5

TABLE OF CONTENTS

Preassessment and Activity Overview

Major Depressive Disorder Novel Treatments for MDD

Conclusions and Postassessment

What you are about to see is a previously recorded live symposium.
Please note that only "home study" credit will be awarded for participating in this archived presentation.
No "live" credits are available.

Postgraduate Healthcare Education, LLC (PHE) is the source of Power-Pak C.E.® continuing education for health care professionals. Our accredited programs assist in meeting the requirements of licensure. PHE provides continuing education for the broad spectrum of health care professionals. This site features a searchable database of accredited Power-Pak C.E.® courses on important topics for today's health care professionals.

PHE customizes Power-Pak C.E.® online for each visitor by creating a personal participant profile. Registered participants may update their contact information, take an exam, receive instant grading, view their exam history, and print certificates for successfully completed programs at any time. Monthly notifications will be sent to participants notifying you of new courses available on the site.